Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian cancer. Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than standard chemotherapy.
Pignata, S., Scambia, G., Ferrandina, M. G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Lombardi, A., Febbraro, A., Del Medico, P., Ferro, A., Scollo, P., Tamberi, S., Brandes, A., Ravaioli, A., Valerio, M., Aitini, E., Natale, D., Scaltriti, L., Greggi, S., Pisano, C., Lorusso, D., Salutari, V., Legge, F., Di Maio, M., Morabito, A., Gallo, C., Perrone, F., Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial, <<JOURNAL OF CLINICAL ONCOLOGY>>, 2011; 29 (27): 3628-3635. [doi:10.1200/JCO.2010.33.8566] [http://hdl.handle.net/10807/3735]
Autori: | ||
Titolo: | Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1200/JCO.2010.33.8566 | |
Data di pubblicazione: | 2011 | |
Abstract: | Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian cancer. Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than standard chemotherapy. | |
Lingua: | Inglese | |
Rivista: | ||
Citazione: | Pignata, S., Scambia, G., Ferrandina, M. G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Lombardi, A., Febbraro, A., Del Medico, P., Ferro, A., Scollo, P., Tamberi, S., Brandes, A., Ravaioli, A., Valerio, M., Aitini, E., Natale, D., Scaltriti, L., Greggi, S., Pisano, C., Lorusso, D., Salutari, V., Legge, F., Di Maio, M., Morabito, A., Gallo, C., Perrone, F., Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial, <<JOURNAL OF CLINICAL ONCOLOGY>>, 2011; 29 (27): 3628-3635. [doi:10.1200/JCO.2010.33.8566] [http://hdl.handle.net/10807/3735] | |
Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |